Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400) – iM Securities | ESS Business Pivot · AMPC Benefits · Earnings Visibility / 2026-07-31 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – SK Securities | MLCC ASP Rise · FCBGA Margin Expansion · Earnings Upward Revision / 2026-07-31 Research
  • [Research] Samsung SDI (006400) – iM Securities | AIDC ESS Demand · US Regulation Benefits · Profit Turnaround / 2026-06-30 Research
  • [Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q3 2024 Earnings Presentation / 2024-10-29 IR Room
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · ADR Listing · Valuation Re-rating / 2026-03-23 Research

Author: ksb220805@gmail.com

[Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28

Posted on July 28, 2026August 23, 2026 By ksb220805@gmail.com
[Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28

Brokerage : DS Investment & Securities Analyst : Minjeong Kim Investment Rating : BUY (Maintained) & Large-Cap Top Pick Target Price : KRW 320,000 (Maintained) Core Momentum : Strong 2Q26 earnings beat driven by steep revenue growth from second-wave new biosimilars including Omlyclo and Eyptozma, with second-half catalysts including Omlyclo 300mg high-dose rollout and Pfizer-Zymfentra…

Read More “[Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28” »

Research, Bio & Healthcare

[Research] Hanwha Ocean (042660) – Kiwoom | High-Price Mix · Merchant Margin Acceleration · 2H Order Intake / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – Kiwoom | High-Price Mix · Merchant Margin Acceleration · 2H Order Intake / 2026-07-28

Brokerage : Kiwoom Securities Analyst : Hangyeol Lee Investment Rating : BUY (Maintained) Target Price : KRW 144,000 (Maintained) Core Momentum : Rapid merchant earnings expansion driven by the higher revenue mix of post-2024 high-price orders and structural cost reductions, with focus shifting to 2H order acceleration across merchant, naval, and offshore divisions 📊 1….

Read More “[Research] Hanwha Ocean (042660) – Kiwoom | High-Price Mix · Merchant Margin Acceleration · 2H Order Intake / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28

Brokerage : iM Securities Analyst : Yongjin Byun Investment Rating : Buy (Maintained) Target Price : KRW 134,000 (Lowered) Core Momentum : Record-high merchant shipbuilding earnings driven by high-price order recognition and cost savings, countered by a target price reduction to reflect near-term sentiment headwinds from the Canadian submarine outcome and delayed US naval legislation…

Read More “[Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28

Brokerage : Shinhan Securities Analyst : Dongheon Lee, Jihan Lee Investment Rating : BUY (Maintained) Target Price : KRW 130,000 (Lowered) Core Momentum : Robust merchant earnings expansion driven by post-2024 high-price LNGC recognition and cost savings, with a diversified portfolio across merchant, offshore, and energy shielding against naval export uncertainties 📊 1. [Valuation &…

Read More “[Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28

Brokerage : SK Securities Analyst : Seunghan Han (R.A : Seoyoung Ko) Investment Rating : BUY (Maintained) Target Price : KRW 134,000 (Maintained) Core Momentum : Sustained recurring profit expansion in merchant ships driven by high-margin 2024–2025 LNGC builds, alongside a balanced focus on total earnings volatility stemming from FX shifts, incentive costs, and fixed-cost…

Read More “[Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28

Brokerage : Eugene Investment & Securities Analyst : Dongheon Lee, Seunghoon Yang Investment Rating : BUY (Maintained) Target Price : KRW 137,000 (Lowered) Core Momentum : Sustained profitability improvement in the merchant ship division as high-price post-2024 orders enter production, with expectations turning toward global naval pipeline opportunities and MASGA progress following the pricing-in of…

Read More “[Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28

Brokerage : Yuanta Securities Analyst : Yongmin Kim Investment Rating : BUY (Maintained) Target Price : KRW 179,000 (Maintained) Core Momentum : Differentiated earnings growth driven by expanding revenue recognition of high-price FY24–25 orders and recurring FX gains under a limited hedging policy during periods of Won weakness 📊 1. [Valuation & Key Financial Metrics]…

Read More “[Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – Hana Securities | Merchant Vessel Margin Expansion · Energy Supply Chain Shift · Order Momentum / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – Hana Securities | Merchant Vessel Margin Expansion · Energy Supply Chain Shift · Order Momentum / 2026-07-28

Brokerage : Hana Securities Analyst : Jaeseon Yoo Investment Rating : BUY (Maintained) Target Price : KRW 175,000 (Maintained) Core Momentum : Sustained margin step-up in merchant ships driven by post-2024 high-price LNGC recognition, positioned for structural order gains across gas carriers, tankers, and offshore plants amid global energy supply chain shifts 📊 1. [Valuation…

Read More “[Research] Hanwha Ocean (042660) – Hana Securities | Merchant Vessel Margin Expansion · Energy Supply Chain Shift · Order Momentum / 2026-07-28” »

Research, Shipbuilding

[Research] Hanwha Ocean (042660) – DS Investment & Securities | Merchant Vessel Profitability · High-Price Mix · MASGA Beneficiary / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com
[Research] Hanwha Ocean (042660) – DS Investment & Securities | Merchant Vessel Profitability · High-Price Mix · MASGA Beneficiary / 2026-07-28

Brokerage : DS Investment & Securities Analyst : Daesung Kim Investment Rating : BUY (Maintained) Target Price : KRW 145,000 (Raised) Core Momentum : Strong profitability expansion in the merchant ship division driven by ~70% recognition of high-price post-2024 vintages and cost optimization, coupled with prime positioning for US naval MASGA programs via Philly Shipyard…

Read More “[Research] Hanwha Ocean (042660) – DS Investment & Securities | Merchant Vessel Profitability · High-Price Mix · MASGA Beneficiary / 2026-07-28” »

Research, Shipbuilding

[Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27

Posted on July 27, 2026August 23, 2026 By ksb220805@gmail.com
[Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27

Brokerage : Mirae Asset Securities Analyst : Seungmin Kim Investment Rating : BUY (Maintained) Target Price : KRW 2,100,000 (Lowered) Core Momentum : Despite lowering the target price due to adjusted Plant 5 utilization timing and broader CDMO sector valuation multiple compression, robust earnings growth is expected driven by full utilization of Plants 1–4 and…

Read More “[Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27” »

Research, Bio & Healthcare

Posts pagination

Previous 1 … 6 7 8 … 31 Next
  • [Research] SK hynix (000660 / SKHY) – Yuanta | AI Inference · Enterprise SSD · Cash Flow / 2026-01-29 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · HBM Market Share · Earnings Growth / 2026-07-01 Research
  • [IR] SK hynix (000660 / SKHY) – Q1 2025 Earnings Presentation / 2025-04-24 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI MLCC Shortage · FCBGA Pricing Power · Valuation Premium / 2026-07-01 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | NAND Pricing · Fab Utilization · Earnings Upgrades / 2026-01-07 Research
  • [Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | De-China Supply Chain · FC-BGA Geopolitics · MLCC Strategic Asset / 2026-06-05 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · SOX Inclusion · HBM Pricing / 2026-06-25 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme